Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Sold as Tranxene, Tranxene Sd. Every FDA application for this active ingredient: 1 branded and 63 generic.
As of Nov 15, 2026, FDA lists 64 applications for Clorazepate Dipotassium (sold as Tranxene, Tranxene Sd), first approved Jun 23, 1972, with 1 new use approved and 0 published complete response letters.
First approved: Jun 23, 1972
Applications: 64
New uses approved: 1
Complete response letters: 0
Medicare spending, 2025: $9.5M
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Product
Part
Spending, 2025
Change
Beneficiaries
Clorazepate Dipotassium
Part D
$9.5M
-16%
22,150
Applications
NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Aurobindo Pharma
Taro
Novitium Pharma